FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2528133039> ?p ?o ?g. }

• W2528133039 endingPage "74700" @default.
• W2528133039 startingPage "74686" @default.
• W2528133039 abstract "// Sougat Misra 1 , Arun Kumar Selvam 1 , Marita Wallenberg 1 , Aditya Ambati 2,3 , András Matolcsy 4 , Isabelle Magalhaes 5 , Gilbert Lauter 6 and Mikael Björnstedt 1 1 Department of Laboratory Medicine, Division of Pathology F46, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden 2 Therapeutic Immunology Unit, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden 3 Centre for Allogeneic Stem Cell Transplantation (CAST), Karolinska University Hospital, Stockholm, Sweden 4 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Faculty of Medicine, Budapest, Üllői út, Hungary 5 Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden 6 Department of Biosciences and Nutrition, NOVUM, Karolinska Institutet, Huddinge, Sweden Correspondence to: Sougat Misra, email: // Mikael Björnstedt, email: // Keywords : acute myeloid leukemia, selenite, all-trans retinoic acid, differentiation, PML/RARA Received : August 04, 2016 Accepted : September 29, 2016 Published : October 08, 2016 Abstract Selective targeting of the PML/RARα oncoprotein demonstrates a successful molecular targeted therapy in acute promyelocytic leukemia (APL) with a typical t(15:17) chromosomal translocation. The zinc-thiolate coordination is critical for structural stability of zinc finger proteins, including the PML moiety of PML/RARα. Based on the known interaction of redox-active selenium compounds with thiolate ligands of zinc, we herein have investigated the abrogatory effects of selenite alone or in combination with all- trans retinoic acid on PML/RARα and the possible effects on differentiation in these cells. At pharmacological concentrations, selenite inhibited the proliferation and survival of APL originated NB4 cells. In combination with ATRA, it potentiated the differentiation of NB4 cells without any differentiating effects of its own as a single agent. Concordant with our hypothesis, PML/RARα oncoprotein expression was completely abrogated by selenite. Increased expression of RAR, PU.1 and FOXO3A transcription factors in the combined treatment suggested the plausible basis for increased differentiation in these cells. We show that selenite at clinically achievable dose targets PML/RARα oncoprotein for degradation and potentiates differentiation of promyelocytic leukemic cells in combination with ATRA. The present investigation reveals the hitherto unknown potential of selenite in targeted abrogation of PML/RARα in APL cells with prospective therapeutic value." @default.
• W2528133039 created "2016-10-14" @default.
• W2528133039 creator A5006660928 @default.
• W2528133039 creator A5043699923 @default.
• W2528133039 creator A5056061995 @default.
• W2528133039 creator A5071887651 @default.
• W2528133039 creator A5073269957 @default.
• W2528133039 creator A5080855592 @default.
• W2528133039 creator A5082886886 @default.
• W2528133039 creator A5088019729 @default.
• W2528133039 date "2016-10-08" @default.
• W2528133039 modified "2023-10-11" @default.
• W2528133039 title "Selenite promotes all-<i>trans</i> retinoic acid-induced maturation of acute promyelocytic leukemia cells" @default.
• W2528133039 cites W1493917229 @default.
• W2528133039 cites W1589900156 @default.
• W2528133039 cites W1594364161 @default.
• W2528133039 cites W1599108883 @default.
• W2528133039 cites W1966597938 @default.
• W2528133039 cites W1974887651 @default.
• W2528133039 cites W1981044274 @default.
• W2528133039 cites W1991834919 @default.
• W2528133039 cites W1993243592 @default.
• W2528133039 cites W1995369623 @default.
• W2528133039 cites W2001142914 @default.
• W2528133039 cites W2002426440 @default.
• W2528133039 cites W2004346657 @default.
• W2528133039 cites W2008085394 @default.
• W2528133039 cites W2011465631 @default.
• W2528133039 cites W2025656277 @default.
• W2528133039 cites W2030421521 @default.
• W2528133039 cites W2030928908 @default.
• W2528133039 cites W2035817692 @default.
• W2528133039 cites W2039079135 @default.
• W2528133039 cites W2039146967 @default.
• W2528133039 cites W2043856858 @default.
• W2528133039 cites W2045959886 @default.
• W2528133039 cites W2049038466 @default.
• W2528133039 cites W2050249118 @default.
• W2528133039 cites W2052912964 @default.
• W2528133039 cites W2054789114 @default.
• W2528133039 cites W2060241324 @default.
• W2528133039 cites W2061147690 @default.
• W2528133039 cites W2063083122 @default.
• W2528133039 cites W2067142409 @default.
• W2528133039 cites W2068322725 @default.
• W2528133039 cites W2068876833 @default.
• W2528133039 cites W2069136008 @default.
• W2528133039 cites W2092036624 @default.
• W2528133039 cites W2111504523 @default.
• W2528133039 cites W2114511168 @default.
• W2528133039 cites W2129338773 @default.
• W2528133039 cites W2134429215 @default.
• W2528133039 cites W2135132221 @default.
• W2528133039 cites W2149902033 @default.
• W2528133039 cites W2170325085 @default.
• W2528133039 cites W4230033805 @default.
• W2528133039 doi "https://doi.org/10.18632/oncotarget.12531" @default.
• W2528133039 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5342695" @default.
• W2528133039 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27732960" @default.
• W2528133039 hasPublicationYear "2016" @default.
• W2528133039 type Work @default.
• W2528133039 sameAs 2528133039 @default.
• W2528133039 citedByCount "14" @default.
• W2528133039 countsByYear W25281330392017 @default.
• W2528133039 countsByYear W25281330392018 @default.
• W2528133039 countsByYear W25281330392019 @default.
• W2528133039 countsByYear W25281330392020 @default.
• W2528133039 countsByYear W25281330392022 @default.
• W2528133039 countsByYear W25281330392023 @default.
• W2528133039 crossrefType "journal-article" @default.
• W2528133039 hasAuthorship W2528133039A5006660928 @default.
• W2528133039 hasAuthorship W2528133039A5043699923 @default.
• W2528133039 hasAuthorship W2528133039A5056061995 @default.
• W2528133039 hasAuthorship W2528133039A5071887651 @default.
• W2528133039 hasAuthorship W2528133039A5073269957 @default.
• W2528133039 hasAuthorship W2528133039A5080855592 @default.
• W2528133039 hasAuthorship W2528133039A5082886886 @default.
• W2528133039 hasAuthorship W2528133039A5088019729 @default.
• W2528133039 hasBestOaLocation W25281330391 @default.
• W2528133039 hasConcept C111441629 @default.
• W2528133039 hasConcept C203014093 @default.
• W2528133039 hasConcept C2776601000 @default.
• W2528133039 hasConcept C2778461978 @default.
• W2528133039 hasConcept C2781121885 @default.
• W2528133039 hasConcept C502942594 @default.
• W2528133039 hasConcept C54355233 @default.
• W2528133039 hasConcept C71924100 @default.
• W2528133039 hasConcept C81885089 @default.
• W2528133039 hasConcept C86803240 @default.
• W2528133039 hasConceptScore W2528133039C111441629 @default.
• W2528133039 hasConceptScore W2528133039C203014093 @default.
• W2528133039 hasConceptScore W2528133039C2776601000 @default.
• W2528133039 hasConceptScore W2528133039C2778461978 @default.
• W2528133039 hasConceptScore W2528133039C2781121885 @default.
• W2528133039 hasConceptScore W2528133039C502942594 @default.
• W2528133039 hasConceptScore W2528133039C54355233 @default.
• W2528133039 hasConceptScore W2528133039C71924100 @default.
• W2528133039 hasConceptScore W2528133039C81885089 @default.

• next